PROGESTERONE COMBINATIONS

The present disclosure describes a method for treating or preventing an inflammatory ocular surface disease or disorder, such as ocular graft-versus-host disease, dry eye, meibomian gland disease, thyroid eye disease, blepharitis, Sjogren's syndrome, peripheral ulcerative keratitis, or Stevens-Johnson syndrome, in a human subject in need thereof, the method comprising (a) administering a topical progesterone composition to the forehead of the subject; (b) administering punctal plugs to the subject; and (c) administering a opical corticosteroid composition, such as loteprednol etabonate ointment, to the eye of the subject. Such administration methods may also be useful in improving corneal health before cataract surgery and/or promoting healing of the cornea after cataract surgery..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 06. März Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

LUO ZHONGHUI KATIE [VerfasserIn]
SAWYER KENNETH I [VerfasserIn]
CHANG WEI-WEI [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-03-06, Last update posted on www.tib.eu: 2024-03-19, Last updated: 2024-03-22

Patentnummer:

EP4103194

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA000459097